CARDIOVASCULAR PHARMACOTHERAPY AND PERIODONTAL OUTCOMES: A NARRATIVE REVIEW
- 29 December 2025
- journal article
- Published by Romanian Association of Oral Rehabilitation in Romanian Journal of Oral Rehabilitation
- Vol. 17 (4) , 6-24
Abstract
Background: Cardiovascular disease and periodontitis commonly coexist, and cardiovascular pharmacotherapy may affect periodontal tissues and clinical indices, thereby influencing treatment planning. Objective: To synthesize clinically relevant associations between major cardiovascular medication classes and periodontal status and to translate these findings into practical considerations for periodontal care. Summary of evidence: Calcium channel blockers provide the most consistent signal, with a strong association with drug-induced gingival overgrowth. Enlargement can promote pseudo-pocketing, impair plaque control, and intensify gingival inflammation; expression is modified by local biofilm burden and supportive periodontal care. Statins show a plausible host-modulatory signal; observational studies and adjunctive trials report improvements in inflammatory parameters and, in selected settings, modest additional reductions in probing depth and clinical attachment gain, but heterogeneity and risk of bias limit certainty. Evidence for ACE inhibitors/angiotensin receptor blockers, beta-blockers, and diuretics is limited and often mediated by xerostomia, frailty, and oral health behaviors. Antiplatelet and anticoagulant therapy mainly affects bleeding-based indices; increased bleeding on probing does not necessarily indicate greater attachment loss. Polypharmacy can amplify xerostomia and complicate home care, while bleeding-based indices may be misleading without concurrent attachment and radiographic endpoints for assessment. Conclusions: Cardiovascular medications can alter periodontal presentation and complicate longitudinal monitoring. Medication-aware history taking (agent, dose, duration, combinations), interpretation anchored in attachment and bone measures, and tailored management of gingival overgrowth, bleeding risk, and xerostomia are recommended. Future research should apply standardized periodontal outcomes and detailed exposure definitions in longitudinal designs and, in pragmatic trials, evaluate whether optimized periodontal care in cardiovascular-medicated patients improves systemic inflammatory and vascular biomarkers.Keywords
This publication has 44 references indexed in Scilit:
- Impact of medications on salivary flow rate in patients with xerostomia: a retrospective study by the Xeromeds ConsortiumClinical Oral Investigations, 2022
- Prevalence of dry mouth in adult patients in primary health careActa Odontologica Scandinavica, 2022
- Longitudinal follow-up study of the association between statin use and chronic periodontitis using national health screening cohort of Korean populationScientific Reports, 2022
- Staging and grading of periodontitis: Framework and proposal of a new classification and case definitionJournal of Periodontology, 2018
- The effect of local and systemic statin use as an adjunct to non-surgical and surgical periodontal therapy—A systematic review and meta-analysisJournal of Dentistry, 2017
- The Active Comparator, New User Study Design in Pharmacoepidemiology: Historical Foundations and Contemporary ApplicationCurrent Epidemiology Reports, 2015
- World Workshop on Oral Medicine VI: a systematic review of medication-induced salivary gland dysfunction: prevalence, diagnosis, and treatmentClinical Oral Investigations, 2015
- Relationships of beta-blockers and anxiolytics intake and salivary secretion, masticatory performance and taste perceptionArchives of Oral Biology, 2010
- In vivo expression of RANKL in the rat dental follicle as determined by laser capture microdissectionArchives of Oral Biology, 2004
- Confounding by Indication in Epidemiologic Studies of Commonly Used AnalgesicsAmerican Journal of Therapeutics, 2002